ClinicalTrials.gg
RecruitingNCT05673915Updated Jan 28, 2026

Study of Transcranial Direct Current Stimulation to Treat Epilepsy

An interventional study of ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) and ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS) in Focal Epilepsy, Generalized Onset Epilepsy and Sleep-related Epileptic Encephalopathy, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Planned enrollment
63rd of 86
30 · median 100
Started
2023
with 2 others
No phase
14 of 102
6 open now
Primary completion
2026-12
later than 3 of 22 live
Registered
84th of 102
by date
Lead sponsor
4 of 102
Mayo Clinic

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 63rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 3 that started in 2023, is one of 14 with no phase, reaches primary completion later than 3 of the 22 other live ones, and was the 84th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.

Read the detailed description

tDCS for treatment of epilepsy has been studied previously with results suggesting that it can lead to a notable seizure reduction for a limited time period after the cessation of stimulation, e.g., about one month. Here, we assess further aspects of tDCS treatment protocols, including the feasibility and safety of at-home use.

03

Conditions studied

  • Focal Epilepsy
  • Generalized Onset Epilepsy
  • Sleep-related Epileptic Encephalopathy

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of generalized onset or focal epilepsy or sleep-related epileptic encephalopathy.
  • Estimated to have at least 2 countable seizures per month or spike-wave index ≥50%.
  • Has not had control with at least 2 anti-seizure medicines.
  • Able to maintain a constant medication for duration of the study (rescue meds allowed).
  • Subject or legally authorized representative is able to understand consent and keep a seizure diary in English.

Exclusion criteria

Exclusion Criteria:

  • A disease likely to progress over course of the study.
  • Psychogenic non-epileptic seizures.
  • Suicide attempt or psychiatric hospitalization past 2 years.
  • A skin condition interfering with scalp electrodes or allergy to silver.
  • Women will verify not pregnant, and if applicable, have a serum pregnancy test.
  • Implanted devices (e.g. pacemakers)-except VNS, which is allowed.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    tDCS Treatment A (Low Amplitude)

    Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.

    Device: ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)

  • Experimental
    tDCS Treatment B (High Amplitude)

    Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.

    Device: ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)

Interventions

  • DeviceActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)

    Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.

  • DeviceActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)

    Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.

06

What researchers measure

Primary outcomes

  1. Seizure Count

    Number of seizures experienced by subjects as determined by self-reported seizure diary

    Time frame: 2 months

Secondary outcomes

  1. EEG interictal discharge frequency

    Number of interictal epileptiform discharges observed on electroencephalogram (EEG)

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2022
First posted
Jan 6, 2023
StartActual
Apr 12, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05673915
Lead sponsor
Mayo Clinic
Responsible party
Brian N. Lundstrom (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 6, 2023
Start date
Apr 12, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Precylla Ruiz
Contact
ruiz.precylla@mayo.edu
507-538-6606
Izzie Meunier
Contact
meunier.isabelle@mayo.edu
507-538-6337
Brian Lundstrom, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion